Elanco Animal Health Incorporated Common Stock
Here’s whether Elanco Animal Health Incorporated Common Stock (ELAN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 41 — healthy momentum range; strong 1-year return of +37.0%; 3-month momentum positive (+10.3%). Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.53% over 10 days). Currently 14.3% off its 52-week high. Score: +3/7.
ELAN is holding above its long-term 200-day MA ($23.61) but has slipped below the 50-day MA ($24.54), pointing to short-term weakness in an otherwise intact trend. An RSI of 41.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +37.0% compares to +20.5% for SPY (beat the market by 16.6%).